Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D007536:Isomerism; D015474:Isotretinoin; D008727:Methotrexate / Q000008:administration & dosage; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011897:Random Allocation; D012042:Registries; D013852:Thiotepa / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D008937:Mitomycins; D016685:Mitomycin; D014212:Tretinoin; D003520:Cyclophosphamide; D013852:Thiotepa; D015474:Isotretinoin; D002945:Cisplatin; D008727:Methotrexate